On January 30, 2018, the Government of Canada posted the Comprehensive and Progressive Partnership for Trans-Pacific Partnership (CPTPP) - Backgrounder. According to the Backgrounder, Canada and other signatories agreed to suspend certain obligations under the Trans-Pacific Partnership (TPP) with respect to intellectual property, patents and pharmaceuticals, including on patent term adjustments to compensate for unreasonable patent office delays and marketing authorization delays. Canada already provides for patent term extension for marketing authorization delays under the Patent Act and Certificate of Supplementary Protection Regulations which came into force September 21, 2017 (as previously reported). On February 20, 2018, Global Affairs Canada subsequently issued a news release announcing the release of the full text of the CPTPP and projected economic impacts of the CPTPP on Canada.
Related Publications & Articles
-
Health Canada’s modernization of clinical trial framework: notice of interim policy and results from consultation
As we previously reported, Health Canada consulted on the framework for clinical trials, including on the new Clinical Trials Regulations and draft and updated guidance documents. Health Canada has no...Read More -
Health Canada issues new and updated guidance for managing therapeutic product shortages
On October 7, 2026, Health Canada published a new Guide on extending expiration dates of marketed drugs in response to drug shortages (GUI-0500).Read More -
Health Canada provides its quarterly update and PMPRB publishes the 10th edition of the Meds Entry Watch report
On October 15, 2026, Health Canada provided its quarterly update summarizing steps it has taken “to make its regulatory processes more modern and efficient, while maintaining high standards for safety...Read More
